Yiming Angko-B announced that the company launched a phase II clinical trial of IMM2510 combined with IMM27M for first-line treatment of patients with advanced hepatocellular carcinoma. The first patient administration was successfully completed to evaluate the initial efficacy and safety of the combination therapy; the phase Ib clinical trial of this combination therapy has determined the recommended phase II dose.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.